Additive Value of High-Density Lipoprotein Cholesterol and C-Reactive Protein Level Assessment for Prediction of 2-year Mortality After Transcatheter Aortic Valve Implantation

被引:8
作者
Zielinski, Kamil [1 ,2 ]
Kalinczuk, Lukasz [1 ]
Chmielak, Zbigniew [1 ]
Mintz, Gary S. [3 ]
Dabrowski, Maciej [1 ]
Pregowski, Jerzy [1 ]
Swierczewski, Michal [1 ,2 ]
Kowalik, Ilona [1 ]
Demkow, Marcin [1 ]
Hryniewiecki, Tomasz [1 ]
Michalowska, Ilona [1 ]
Witkowski, Adam [1 ]
机构
[1] Inst Cardiol, Warsaw, Poland
[2] Med Univ Warsaw, Warsaw, Poland
[3] Cardiovasc Res Fdn, New York, NY USA
关键词
INFLAMMATION; ASSOCIATION; BIOMARKERS; DISEASE; CANCER; RISK; CRP;
D O I
10.1016/j.amjcard.2020.03.037
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Available prediction models are inaccurate in elderly who underwent transcatheter aortic valve implantation (TAVI). The aim of present study was to analyze the separate and combined prognostic values of baseline HDL-C and C-reactive protein (CRP) levels in patients treated successfully with TAVI who had complete 2-year follow-up. We analyzed 334 patients treated with TAVI from 01/2010 to 07/2017 who had measurements of HDL-C and CRP on admission or during qualification for the procedure. Baseline HDL-C <= 46 mg/dl (areas under the curve [AUC] = 0.657) and CRP >= 0.20 mg/dl (AUC = 0.634) were predictive of 2-year mortality. After stratification with both cutoffs, patients with low HDL-C and concomitant high CRP most often had LVEF <= 50% and were high risk as per EuroSCORE II. Those with isolated CRP elevation had the lowest frequency of LVEF <= 50%, but more sarcopenia (based on psoas muscle area). After adjustment in the multivariate analysis for other identified predictors including EuroSCORE II and statin therapy, isolated HDL-C <= 46 mg/dl (identified in 40 patients) and isolated CRP >= 0.20 mg/dl (n = 109) were both independent predictors of 2-year mortality (hazard ratio [HR] = 2.92 and HR = 2.42, respectively) compared with patients with both markers within established cutoffs (n = 105) who had the lowest 2-year mortality (9.5%). Patients with both markers exceeding cutoffs (n = 80) had the highest risk (HR = 4.53) with 2-year mortality of 42.5%. High CRP was associated with increased mortality within the first year of follow-up, whereas low HDL-C increased mortality in the second year. The combination of both markers with EuroSCORE II enhanced mortality prediction (AUC = 0.697). In conclusion, low baseline HDL-C and high CRP jointly contribute to the prediction of increased all-cause mortality after TAVI. (C) 2020 Elsevier Inc. All rights reserved.
引用
收藏
页码:66 / 72
页数:7
相关论文
共 38 条
  • [31] Impact of Combined C-Reactive Protein and High-Density Lipoprotein Cholesterol Levels on Long-Term Outcomes in Patients With Coronary Aitery Disease After a First Percutaneous Coronary Intervention
    Ogita, Manabu
    Miyauchi, Katsumi
    Tsuboi, Shuta
    Shitara, Jun
    Endo, Hirohisa
    Wada, Hideki
    Doi, Shinichiro
    Naito, Ryo
    Konishi, Hirokazu
    Dohi, Tomotaka
    Kasai, Takatoshi
    Tamura, Hiroshi
    Okazaki, Shinya
    Suwa, Satoru
    Daida, Hiroyuki
    AMERICAN JOURNAL OF CARDIOLOGY, 2015, 116 (07) : 999 - 1002
  • [32] Reaching C-Reactive Protein and Low-Density Lipoprotein Cholesterol Goals in Dyslipidemic Patients (from the Lipid Treatment Assessment Project [L-TAP] 2)
    Chiang, Cheng-Wen
    Santos, Raul D.
    Waters, David D.
    Messig, Michael
    Tarasenko, Lisa
    Jukema, J. Wouter
    Ferrieres, Jean
    Foody, JoAnne
    Seung, Ki-Bae
    AMERICAN JOURNAL OF CARDIOLOGY, 2011, 107 (11) : 1639 - 1643
  • [33] Inverse relationship between high-density lipoprotein cholesterol raising and high-sensitivity C-reactive protein reduction in older patients treated with lipid-lowering therapy
    Brown, W. Virgil
    Foody, JoAnne M.
    Zieve, Franklin J.
    Tomassini, Joanne E.
    Shah, Arvind
    Tershakovec, Andrew M.
    JOURNAL OF CLINICAL LIPIDOLOGY, 2016, 10 (01) : 116 - 123
  • [34] Analysis and modelling of cholesterol and high-density lipoprotein cholesterol changes across the range of C-reactive protein levels in clinical practice as an aid to better understanding of inflammation-lipid interactions
    Johnsson, Hanna
    Panarelli, Maurizio
    Cameron, Allan
    Sattar, Naveed
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (08) : 1495 - 1499
  • [35] Gender differences in the association between the uric acid to high-density lipoprotein cholesterol ratio and diabetes risk: a mediation analysis of c-reactive protein, triglycerides, and insulin resistance
    Yin, Jianming
    Zheng, Chuanjie
    Li, Zhan
    Chang, Ying
    Cao, Lingyong
    Qu, Yiqian
    LIPIDS IN HEALTH AND DISEASE, 2024, 23 (01)
  • [36] Elevation of B-Type Natriuretic Peptide at Discharge is Associated With 2-Year Mortality After Transcatheter Aortic Valve Replacement in Patients With Severe Aortic Stenosis: Insights From a Multicenter Prospective OCEAN-TAVI (Optimized Transcatheter Valvular Intervention-Transcatheter Aortic Valve Implantation) Registry
    Mizutani, Kazuki
    Hara, Masahiko
    Iwata, Shinichi
    Murakami, Takashi
    Shibata, Toshihiko
    Yoshiyama, Minoru
    Naganuma, Toru
    Yamanaka, Futoshi
    Higashimori, Akihiro
    Tada, Norio
    Takagi, Kensuke
    Araki, Motoharu
    Ueno, Hiroshi
    Tabata, Minoru
    Shirai, Shinichi
    Watanabe, Yusuke
    Yamamoto, Masanori
    Hayashida, Kentaro
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2017, 6 (07):
  • [37] Apolipoprotein B/A-I and total cholesterol/high-density lipoprotein cholesterol ratios both predict cardiovascular events in the general population independently of nonlipid risk factors, albuminuria and C-reactive protein
    Kappelle, P. J. W. H.
    Gansevoort, R. T.
    Hillege, J. L.
    Wolffenbuttel, B. H. R.
    Dullaart, R. P. F.
    JOURNAL OF INTERNAL MEDICINE, 2011, 269 (02) : 232 - 242
  • [38] High-sensitivity C-reactive protein, low-density lipoprotein cholesterol and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care) trial
    Hwang, You-Cheol
    Morrow, David A.
    Cannon, Christopher P.
    Liu, Yuyin
    Bergenstal, Richard
    Heller, Simon
    Mehta, Cyrus
    Cushman, William
    Bakris, George L.
    Zannad, Faiez
    White, William B.
    DIABETES OBESITY & METABOLISM, 2018, 20 (03) : 654 - 659